Answers are grounded in this paper and cite their sources.
Telemedicine (TM) has demonstrated several advantages in the management of chronic diseases, but evidence in pediatric epilepsy is limited. We compared TM with traditional in-person follow-up for pediatric epilepsy. A single-center, prospective, nonrandomized, open-label, noninferiority clinical study was conducted from May 2022 to April 2023. Group assignment was determined by the consultation modality at enrollment, with crossover permitted. The primary outcome was seizure control at 6 months. Secondary outcomes included antiseizure medication (ASM)–related adverse events, emergency department (ED) visits for epilepsy-related concerns, and medication adherence. The primary analysis was performed on an intention-to-treat basis, with a prespecified noninferiority margin of 0.1. Among 190 patients, 55 received TM and 135 received in-person care. Seizure worsening occurred in 16.4% vs 26.7%, respectively (risk difference −10.3% [95% CI, −22.6% to 2.0%]). ASM-related adverse events and ED visits were comparable. TM consultation may be a feasible, noninferior alternative for selective pediatric epilepsy follow-up. Clinical trial registration: ClinicalTrials.gov, https://clinicaltrials.gov/study/NCT05418257 , NCT05418257.
No takes yet. Share an insight, caveat, or question.
Song et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: